Protocol Ledger

NCT07742735 · Phase III · RECRUITING

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

Interventional Phase III clinical trial protocol NCT07742735 sponsored by VectivBio AG in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-01 Enrollment: 124 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07742735
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)124 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07742735
Protocol FieldVerified Registry Value
NCT IdentifierNCT07742735
Consolidated Lead SponsorVectivBio AG
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment124 participants (ESTIMATED)
Registered Start Date2026-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI